Evaluation of moxifloxacin 0.5% in treatment of nonperforated bacterial corneal ulcers: A randomized controlled trial

Ophthalmology

Volumn 120, Issue 6, 2013, Pages 1173-1178

  Sharma, Namrata ^a   Goel, Manik ^a   Bansal, Shubha ^a   Agarwal, Prakashchand ^a   Titiyal, Jeewan S ^a   Upadhyaya, Ashish D ^b   Vajpayee, Rasik B ^a,c  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CEFAZOLIN; EYE DROPS; MOXIFLOXACIN; TOBRAMYCIN SULFATE;

ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL EYE INFECTION; BACTERIAL KERATITIS; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; CORNEA ULCER; DRUG EFFICACY; DRUG SAFETY; EPITHELIZATION; FOLLOW UP; HUMAN; KLEBSIELLA; MAJOR CLINICAL STUDY; MONOTHERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS PNEUMONIAE; TREATMENT DURATION; ULCER HEALING; VISUAL ACUITY;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; BACTERIA; CEFAZOLIN; CORNEA; CORNEAL ULCER; DRUG EVALUATION; DRUG THERAPY, COMBINATION; EYE INFECTIONS, BACTERIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; PREVALENCE; PROSPECTIVE STUDIES; QUINOLINES; THERAPEUTIC EQUIVALENCY; TOBRAMYCIN; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 84878620782     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2012.11.013     Document Type: Article

References (40)

1. S.D. McLeod, L.D. LaBree, R. Tayyanipour The importance of initial management in the treatment of severe infectious corneal ulcers Ophthalmology 102 1995 1943 1948
2. J.P. Whitcher, M. Srinivasan, M.P. Upadhyay Corneal blindness: a global perspective Bull World Health Organ 79 2001 214 221
3. S. Polack, S. Brooker, H. Kuper Mapping the global distribution of trachoma Bull World Health Organ 83 2005 913 919
4. P. Asbell, S. Stenson Ulcerative keratitis: survey of 30 years' laboratory experience Arch Ophthalmol 100 1982 77 80
5. T.J. Liesegang, R.K. Forster Spectrum of microbial keratitis in South Florida Am J Ophthalmol 90 1980 38 47
6. J.L. Baum Initial therapy of suspected microbial corneal ulcers. I. Broad antibiotic therapy based on prevalence of organisms Surv Ophthalmol 24 1979 97 105
7. F. Schaefer, O. Bruttin, L. Zografos, Y. Guex-Crosier Bacterial keratitis: a prospective clinical and microbiological study Br J Ophthalmol 85 2001 842 847
8. Y.W. Ibrahim, D.L. Boase, I.A. Cree Epidemiological characteristics, predisposing factors and microbiological profiles of infectious corneal ulcers: the Portsmouth corneal ulcer study Br J Ophthalmol 93 2009 1319 1324
9. C.N. Ly, J.N. Pham, P.R. Badenoch Bacteria commonly isolated from keratitis specimens retain antibiotic susceptibility to fluoroquinolones and gentamicin plus cephalothin Clin Experiment Ophthalmol 34 2006 44 50
10. R.A. Hyndiuk, R.A. Eiferman, D.R. Caldwell Ciprofloxacin Bacterial Keratitis Study Group Comparison of ciprofloxacin ophthalmic solution 0.3% to fortified tobramycin-cefazolin in treating bacterial corneal ulcers Ophthalmology 103 1966 1854 1862
11. K.R. Wilhelmus, R.A. Hyndiuk, D.R. Caldwell Ciprofloxacin Ointment/Bacterial Keratitis Study Group. 0.3% ciprofloxacin ophthalmic ointment in the treatment of bacterial keratitis Arch Ophthalmol 111 1993 1210 1218
12. D.J. Parks, D.A. Abrams, F.A. Sarfarazi, H.R. Katz Comparison of topical ciprofloxacin to conventional antibiotic therapy in the treatment of ulcerative keratitis Am J Ophthalmol 115 1993 471 477
13. T.P. O'Brien, M.G. Maguire, N.E. Fink Bacterial Keratitis Study Research Group Efficacy of ofloxacin vs cefazolin and tobramycin in the therapy for bacterial keratitis Report from the Bacterial Keratitis Study Research Group Arch Ophthalmol 113 1995 1257 1265
14. N.V. Prajna, C. George, S. Selvaraj Bacteriologic and clinical efficacy of ofloxacin 3% versus ciprofloxacin 0.3% ophthalmic solutions in the treatment of patients with culture-positive bacterial keratitis Cornea 20 2001 175 178
15. D.B. Jones Initial therapy of suspected microbial corneal ulcers. II. Specific antibiotic therapy based on corneal smears Surv Ophthalmol 24 1979 97 105-16
16. H.G. Bennett, J. Hay, C.M. Kirkness Antimicrobial management of presumed microbial keratitis: guidelines for treatment of central and peripheral ulcers Br J Ophthalmol 82 1998 137 145
17. T.P. O'Brien Bacterial keratitis C.S. Foster, D.T. Azar, C.H. Dohlman, Smolin and Thoft's The Cornea: Scientific Foundations and Clinical Practice 4th ed. 2005 Lippincott Williams & Wilkins Philadelphia 235 288
18. S.V. Scoper Review of third- and fourth-generation fluoroquinolones in ophthalmology: in-vitro and in-vivo efficacy Adv Ther 25 2008 979 994
19. J.M. Blondeau Fluoroquinolones: mechanism of action, classification, and development of resistance Surv Ophthalmol 49 suppl 2004 S73 S78
20. L.M. Fisher, V.J. Heaton Dual activity of fluoroquinolones against Streptococcus pneumoniae [letter] J Antimicrob Chemother 51 2003 463 464 author reply 464-5
21. A.B. Khodursky, E.L. Zechiedrich, N.R. Cozzarelli Topoisomerase IV is a target of quinolones in Escherichia coli Proc Natl Acad Sci U S A 92 1995 11801 11805
22. D.M. Breines, S. Ouabdesselam, E.Y. Ng Quinolone resistance locus nfxD of Escherichia coli is a mutant allele of the parE gene encoding a subunit of topoisomerase IV Antimicrob Agents Chemother 41 1997 175 179
23. E. Pestova, J.J. Millichap, G.A. Noskin, L.R. Peterson Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones J Antimicrob Chemother 45 2000 583 590
24. B.E. Bowe, J.W. Snyder, R.A. Eiferman An in vitro study of the potency and stability of fortified ophthalmic antibiotic preparations Am J Ophthalmol 111 1991 686 689
25. J.F. Charlton, K.P. Dalla, A. Kniska Storage of extemporaneously prepared ophthalmic antimicrobial solutions Am J Health Syst Pharm 55 1998 463 466
26. M.K. Arici, Z. Sümer, C. Güler In vitro potency and stability of fortified ophthalmic antibiotics Aust N Z J Ophthalmol 27 1999 426 430
27. V. Karampatakis, T. Papanikolaou, M. Giannousis Stability and antibacterial potency of ceftazidime and vancomycin eyedrops reconstituted in BSS against Pseudomonas aeruginosa and Staphylococcus aureus Acta Ophthalmol 87 2009 555 558
28. M.L. Gilbert, K.R. Wilhelmus, M.S. Osato Comparative bioavailability and efficacy of fortified topical tobramycin Invest Ophthalmol Vis Sci 28 1987 881 885
29. N. Gangopadhyay, M. Daniell, L. Weih, H.R. Taylor Fluoroquinolone and fortified antibiotics for treating bacterial corneal ulcers Br J Ophthalmol 84 2000 378 384
30. C.P. Lin, M. Boehnke Effect of fortified antibiotic solutions on corneal epithelial wound healing Cornea 19 2000 204 206
31. V.M. Shah, R. Tandon, G. Satpathy Randomized clinical study for comparative evaluation of fourth-generation fluoroquinolones with the combination of fortified antibiotics in the treatment of bacterial corneal ulcers Cornea 29 2010 751 757
32. M. Constantinou, M. Daniell, G.R. Snibson Clinical efficacy of moxifloxacin in the treatment of bacterial keratitis: a randomized clinical trial Ophthalmology 114 2007 1622 1629
33. J. Blair, W. Hodge, S. Al-Ghamdi Comparison of antibiotic-only and antibiotic-steroid combination treatment in corneal ulcer patients: double-blinded randomized clinical trial Can J Ophthalmol 46 2011 40 45
34. M. Srinivasan, J. Mascarenhas, R. Rajaraman Steroids for Corneal Ulcers Trial Group Corticosteroids for bacterial keratitis: the Steroids for Corneal Ulcers Trial (SCUT) Arch Ophthalmol 130 2012 143 150
35. M. Moshirfar, G. Mirzaian, V. Feiz, P.C. Kang Fourth-generation fluoroquinolone-resistant bacterial keratitis after refractive surgery J Cataract Refract Surg 32 2006 515 518
36. V. Jhanji, N. Sharma, G. Satpathy, J. Titiyal Fourth-generation fluoroquinolone-resistant bacterial keratitis J Cataract Refract Surg 33 2007 1488 1489
37. M. Moshirfar, J.J. Meyer, L. Espandar Fourth-generation fluoroquinolone-resistant mycobacterial keratitis after laser in situ keratomileusis J Cataract Refract Surg 33 2007 1978 1981
38. P. Garg, S. Sharma, G.N. Rao Ciprofloxacin-resistant Pseudomonas keratitis Ophthalmology 106 1999 1319 1323
39. M.E. Snyder, H.R. Katz Ciprofloxacin-resistant bacterial keratitis Am J Ophthalmol 114 1992 336 338
40. D.Y. Kunimoto, S. Sharma, P. Garg, G.N. Rao In vitro susceptibility of bacterial keratitis pathogens to ciprofloxacin: emerging resistance Ophthalmology 106 1999 80 85